FUNCTIONAL CONSEQUENCES OF NATURAL HIV-1 ENV GENE DIVERS
FUNCTIONAL CONSEQUENCES OF NATURAL HIV-1 ENV GENE DIVERS
批准号:
3085434
负责人:
STEVEN E COUTRE
金额:
$4.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-01-01 至 1992-08-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
One of the greatest difficulties perceived for the development of an
effective HIV vaccine is the potential for escape from protective
immunity through generation of viral diversity, especially within the
envelope protein. Fueling this concern is the demonstration of narrow,
virus type-specific neutralizing activity when patient sera, collected
during the early stages of infection, are tested against a variety of
virus isolates. Although the major neutralizing determinant of the
envelope surface protein gene has been identified (the "V3 loop", most
of the escape-from-neutralization mutations that have been mapped to
date fall outside V3, indicating that the context within which this
determinant is placed is critical to its recognition.
This Physician Scientist Award is intended to provide the applicant with
the necessary conceptual background and laboratory training in the
biology of HIV, with specific emphasis on the correlation between
molecular genetic diversity and biologically-relevant, functional
characteristics. It is designed to allow for the development of the
applicant as an independent biomedical investigator in order to enable
the pursuit of a research career as a physician-scientist.
Phase I will emphasize study and research training in molecular biology,
virology, and immunology. It will focus on the development and
application of techniques designed to investigate the antigenic
diversity of HIV-1 including the transfer of whole env genes from
several HIV-1 genomes isolated directly from the blood of a single
infected individual into vaccinia virus expression vectors. As part of
a comprehensive study of the functional consequences of viral gene
diversity, Phase II will involve the classification of the env genes in
these constructs according to their neutralization susceptibility and
recognition by cytotoxic T lymphocytes. Following these initial
classification studies, chimeric envelope genes will be generated
between antigenically divergent envelopes to map neutralization
determinants and T-cell epitopes.
These studies will also be expanded to other tissues from the same
individual as well as from different time points when the clinical
manifestation of disease has changed in order to identify determinants
of tissue tropism and virulence. This approach will also be applied to
a different individual whose mode of acquisition of HIV-1 differed from
the individual under study.
The eventual aim of these studies is to determine the antigenic
diversity of virus and response to it within an individual, and to
identify sites within env which control display of critical epitopes,
all relevant to formulation of an effective HIV vaccine. The
educational and training aspects of this proposal will also allow the
applicant to gain the expertise necessary to pursue basic studies in the
biology of human retroviruses, including HIV-1, as an independent
investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SHEPHERD: SAFETY IN HEMOLYTIC PNH PATIENTS TREATED WITH ECULIZUMAB
-
批准号:7605233
-
项目类别:
-
资助金额:$2.34万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
CLINICAL TRIAL: CAT-8015 IN PATIENTS WITH RELAPSED OR REFRACTORY HAIRY CELL LEUK
-
批准号:7717934
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
ECULIZUMAB IN PATIENTS WITH TRANSFUSION DEPENDANT, HEMOLYTIC PNH
-
批准号:7605234
-
项目类别:
-
资助金额:$3.22万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
ADULT PATIENTS W/ RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:7605250
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
CLINICAL TRIAL: ADULT PATIENTS W/RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBL
-
批准号:7717899
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
CLINICAL TRIAL: ECULIZUMAB IN PATIENTS WITH TRANSFUSION DEPENDANT, HEMOLYTIC (PN
-
批准号:7717886
-
项目类别:
-
资助金额:$0.26万
-
财政年份:2007
-
负责人:STEVEN E COUTRE
-
依托单位:
SHEPHERD: SAFETY IN HEMOLYTIC PNH PATIENTS TREATED WITH ECULIZUMAB
-
批准号:7375309
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2005
-
负责人:STEVEN E COUTRE
-
依托单位:
PATIENTS WITH TRANSFUSION DEPENDANT (PNH)
-
批准号:7375310
-
项目类别:
-
资助金额:$0.89万
-
财政年份:2005
-
负责人:STEVEN E COUTRE
-
依托单位:
USING ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS
-
批准号:7375282
-
项目类别:
-
资助金额:$0.93万
-
财政年份:2005
-
负责人:STEVEN E COUTRE
-
依托单位:
ANTIB1 ANTIBODY FOR B CELL CHRONIC LYMPHOCYTIC LEUKEMIA
-
批准号:6486086
-
项目类别:
-
资助金额:$13.47万
-
财政年份:2000
-
负责人:STEVEN E COUTRE
-
依托单位:
海外基金